Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

04/11/25 • 7 min

1 Listener

In this episode, we break down the ANNEXA-I randomized trial, which looked at patients with factor Xa inhibitor-associated intracerebral hemorrhage. The study compared andexanet alfa, a targeted reversal agent, with usual care (mainly prothrombin complex concentrate).

The results? Andexanet showed better hemostatic control and more effectively reduced hematoma expansion (67% vs. 53.1%), with a 94.5% median drop in anti-factor Xa activity. But the benefit came with a trade-off—higher rates of thrombotic events, particularly ischemic stroke.

We dive into the clinical implications of these findings and what they mean for balancing bleeding control with thrombotic risk. Whether you're managing ICH cases or staying updated on anticoagulation reversal strategies, this one’s for you.

Previous Episode

Emergency Medicine Is (NOT) Dead

In this episode of 'Talking Shift,' the host welcomes Dr. Chris Doty, an important figure in emergency medicine, to discuss his journey and the current state of the specialty. Dr. Doty reflects on a crisis from two years ago where a significant number of emergency medicine residency spots went unmatched, but more recent data shows improvement. They explore changes in residency program requirements, particularly the potential shift from three-year to four-year programs, and the implications of such modifications. The conversation also touches on the impact of the pandemic on the perception and reality of working in emergency medicine, the financial pressures of medical education, and the trend towards shorter, more manageable training periods. Additionally, they discuss fellowships, emerging trends, and the critical issue of burnout, especially highlighted during the pandemic. Dr. Doty emphasizes the importance of choosing the right residency program and the vital need for systemic changes to support healthcare professionals better.

Next Episode

Haloperidol for the Treatment of Delirium in ICU Patients

In this episode, we look at the latest study on haloperidol for ICU delirium from the New England Journal of Medicine. While haloperidol didn’t increase days alive and out of the hospital, it did show a lower risk of death—a finding that could influence how we approach treatment. Tune in for a quick breakdown of what this means for ICU care and future directions in managing delirium.